Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study

Figures & data

Figure 1. Diagrammatic representation of the sites of IDB injection.

Table 1. Outcome of medical treatment of the studied patients with OAB.

			Failed medical therapy (n = 43)
Time	Outcome data	Successful medical therapy (n = 48)	Intolerant to continue (n = 9)	Failure to respond (n = 22)	Recurrent OAB (n = 12)
Initiation of therapy	OABSS, mean (SD)	9.8 (1.1)	12.3 (1.6)	14.3 (0.9)	13.4 (1.1)
	PPBC score, mean (SD)	4.8 (0.9)	5.1 (0.6)	5.1 (0.8)	4.8 (0.6)
Termination of therapy	Time, mean (SD)	12 months	48.7 (10.2) days	3 months	6 (1.1) months
	OABSS, mean (SD)	4.8 (1.3)*	6.7 (1)*	13.4 (1.1)	12.4 (0.9)
	PPBC score, mean (SD)	2.1 (0.6)*	2.7 (0.9)*	5 (0.6)	4.5 (0.7)

*Significant vs time of initiation of therapy.

Figure 2. Consolidated Standards of Reporting Trials (CONSORT) flow chart.

Table 2. Objective evaluation of the outcomes of the studied patients with OAB.

Variable		At start of treatment, mean (SD)	At 12-month follow-up, mean (SD)
Bladder capacity	EBC, mL	315.6 (3)
	MBC, mL	173.9 (41.4)*	257.9 (68.4)*†
	% of deficit	42.4 (15.4)	12.6 (27.2)†
Uroflowmetry	Voided volume, mL	117.4 (28)	168.7 (40.8)†
	Qmax, mL/s	16.5 (6.1)	24 (4.8)†
	PVR, mL	25.2 (10.6)	12.2 (3.5)†

*Significant difference vs expected capacity; †significant difference vs time of initiation of therapy (baseline).

Figure 3. Subjective outcome of the patients with OAB who underwent IDB injections. m, months.